JP2016511823A5 - - Google Patents

Download PDF

Info

Publication number
JP2016511823A5
JP2016511823A5 JP2015553864A JP2015553864A JP2016511823A5 JP 2016511823 A5 JP2016511823 A5 JP 2016511823A5 JP 2015553864 A JP2015553864 A JP 2015553864A JP 2015553864 A JP2015553864 A JP 2015553864A JP 2016511823 A5 JP2016511823 A5 JP 2016511823A5
Authority
JP
Japan
Prior art keywords
kininogen
intact
value
cut
pkal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015553864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511823A (ja
JP6444315B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/012107 external-priority patent/WO2014113712A1/en
Publication of JP2016511823A publication Critical patent/JP2016511823A/ja
Publication of JP2016511823A5 publication Critical patent/JP2016511823A5/ja
Application granted granted Critical
Publication of JP6444315B2 publication Critical patent/JP6444315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015553864A 2013-01-20 2014-01-17 ブラジキニン媒介障害の評価および治療 Active JP6444315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754607P 2013-01-20 2013-01-20
US61/754,607 2013-01-20
PCT/US2014/012107 WO2014113712A1 (en) 2013-01-20 2014-01-17 Evaluation and treatment of bradykinin-mediated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018221155A Division JP6772237B2 (ja) 2013-01-20 2018-11-27 ブラジキニン媒介障害の評価および治療

Publications (3)

Publication Number Publication Date
JP2016511823A JP2016511823A (ja) 2016-04-21
JP2016511823A5 true JP2016511823A5 (cg-RX-API-DMAC7.html) 2017-02-23
JP6444315B2 JP6444315B2 (ja) 2018-12-26

Family

ID=51210106

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015553864A Active JP6444315B2 (ja) 2013-01-20 2014-01-17 ブラジキニン媒介障害の評価および治療
JP2018221155A Active JP6772237B2 (ja) 2013-01-20 2018-11-27 ブラジキニン媒介障害の評価および治療
JP2020164435A Pending JP2021008483A (ja) 2013-01-20 2020-09-30 ブラジキニン媒介障害の評価および治療
JP2022029441A Active JP7496380B2 (ja) 2013-01-20 2022-02-28 ブラジキニン媒介障害の評価および治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018221155A Active JP6772237B2 (ja) 2013-01-20 2018-11-27 ブラジキニン媒介障害の評価および治療
JP2020164435A Pending JP2021008483A (ja) 2013-01-20 2020-09-30 ブラジキニン媒介障害の評価および治療
JP2022029441A Active JP7496380B2 (ja) 2013-01-20 2022-02-28 ブラジキニン媒介障害の評価および治療

Country Status (21)

Country Link
US (2) US11156612B2 (cg-RX-API-DMAC7.html)
EP (3) EP4234583A3 (cg-RX-API-DMAC7.html)
JP (4) JP6444315B2 (cg-RX-API-DMAC7.html)
KR (3) KR102523810B1 (cg-RX-API-DMAC7.html)
CN (2) CN111044725B (cg-RX-API-DMAC7.html)
AU (4) AU2014207420B2 (cg-RX-API-DMAC7.html)
CA (2) CA2897336C (cg-RX-API-DMAC7.html)
CY (1) CY1122164T1 (cg-RX-API-DMAC7.html)
DK (1) DK2948479T3 (cg-RX-API-DMAC7.html)
ES (1) ES2692408T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181734T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041332T2 (cg-RX-API-DMAC7.html)
IL (2) IL273688B2 (cg-RX-API-DMAC7.html)
LT (1) LT2948479T (cg-RX-API-DMAC7.html)
PL (1) PL2948479T3 (cg-RX-API-DMAC7.html)
PT (1) PT2948479T (cg-RX-API-DMAC7.html)
RS (1) RS57890B1 (cg-RX-API-DMAC7.html)
SI (1) SI2948479T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800563T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815856T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014113712A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
CN110658337B (zh) 2013-10-21 2023-06-16 武田药品工业株式会社 自身免疫性疾病的诊断和治疗
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
CA3290174A1 (en) * 2015-03-30 2026-03-02 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EA201891002A1 (ru) * 2015-10-19 2018-11-30 Дайэкс Корп. Иммунологический анализ для определения расщепленного высокомолекулярного кининогена
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2017106504A1 (en) * 2015-12-15 2017-06-22 Dyax Corp. Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
ME03794B (me) 2016-05-31 2021-04-20 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
IL314752A (en) * 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system
WO2018053244A1 (en) * 2016-09-16 2018-03-22 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
US20200407771A1 (en) * 2018-02-22 2020-12-31 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
AU2020392243A1 (en) 2019-11-28 2022-06-16 Regenxbio Inc. Microdystrophin gene therapy constructs and uses thereof
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021202948A2 (en) * 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) * 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) * 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU2548992A (en) * 1991-08-13 1993-03-16 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第xii因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Hcvコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) * 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009051259A1 (ja) * 2007-10-18 2009-04-23 Miyazaki Prefectural Industrial Support Foundation 肝疾患診断用バイオマーカー
EP2215256A1 (en) 2007-10-22 2010-08-11 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE FROM PLASMA CALLICINE INHIBITORS
AU2013205086A1 (en) * 2009-01-06 2013-05-16 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
WO2012009447A2 (en) 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
JP5937612B2 (ja) 2010-12-02 2016-06-22 ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company 血液安定剤を含む採血用デバイス
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
WO2012170945A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
EP2950718A4 (en) 2013-02-01 2016-09-21 Becton Dickinson Co BLUTSAMMELVORRICHTUNGEN WITH CONTACT PATH -HEMMENDEN ADDITIVES
CN110658337B (zh) 2013-10-21 2023-06-16 武田药品工业株式会社 自身免疫性疾病的诊断和治疗
CN105873951A (zh) 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
EA201891002A1 (ru) 2015-10-19 2018-11-30 Дайэкс Корп. Иммунологический анализ для определения расщепленного высокомолекулярного кининогена

Similar Documents

Publication Publication Date Title
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
JP2017524130A5 (cg-RX-API-DMAC7.html)
JP2016536012A5 (cg-RX-API-DMAC7.html)
JP2017500584A5 (cg-RX-API-DMAC7.html)
Alonso et al. Fungal infection in neural tissue of patients with amyotrophic lateral sclerosis
JP2010516678A5 (cg-RX-API-DMAC7.html)
JP2018511611A5 (cg-RX-API-DMAC7.html)
Coskuner et al. Adenosine triphosphate (ATP) reduces amyloid-β protein misfolding in vitro
JP2017505897A5 (cg-RX-API-DMAC7.html)
JP2015513370A5 (cg-RX-API-DMAC7.html)
JP2019502095A5 (cg-RX-API-DMAC7.html)
JP2020516289A5 (cg-RX-API-DMAC7.html)
JP2014518377A5 (cg-RX-API-DMAC7.html)
CN103328501A (zh) 新的生物标记及其在诊断、治疗孤独症中的用途
JP2018523105A5 (cg-RX-API-DMAC7.html)
NO20074610L (no) Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX385216B (es) Prueba de diagnostico basada en fragmento de rgma.
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
WO2008089135A3 (en) Identification of biomarkers predictive of dasatinib effects in cancer cells
Farjat-Pasos et al. Transcatheter patent foramen ovale closure in stroke patients with thrombophilia: current status and future perspectives
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
BR112016021714A2 (pt) imunoensaio e anticorpos para a detecção de cromogranina a
WO2015048804A3 (en) Protein biomarker and uses thereof
Khattar et al. Pulmonary hypertension: an unexplored risk factor for stroke in patients with atrial fibrillation